D.A. Davidson & CO. Makes New Investment in Astrana Health, Inc. (NASDAQ:ASTH)

D.A. Davidson & CO. acquired a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 26,565 shares of the company’s stock, valued at approximately $1,539,000. D.A. Davidson & CO. owned about 0.05% of Astrana Health at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. SteelPeak Wealth LLC purchased a new stake in Astrana Health in the third quarter valued at about $39,398,000. Loomis Sayles & Co. L P acquired a new stake in Astrana Health in the 3rd quarter worth approximately $30,251,000. NorthCrest Asset Manangement LLC purchased a new stake in Astrana Health during the 3rd quarter worth approximately $26,704,000. Charles Schwab Investment Management Inc. acquired a new position in Astrana Health during the 3rd quarter valued at approximately $25,945,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Astrana Health in the third quarter worth $13,383,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ASTH shares. TD Cowen assumed coverage on Astrana Health in a research report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. KeyCorp assumed coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Robert W. Baird lifted their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Truist Financial increased their price target on shares of Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $65.17.

Astrana Health Stock Performance

ASTH opened at $43.25 on Friday. The firm has a fifty day moving average price of $52.79 and a 200 day moving average price of $48.00. Astrana Health, Inc. has a 1 year low of $32.32 and a 1 year high of $63.20. The stock has a market cap of $2.43 billion, a P/E ratio of 33.27, a P/E/G ratio of 1.99 and a beta of 1.24. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the prior year, the company posted $0.47 EPS. Equities research analysts anticipate that Astrana Health, Inc. will post 1.17 earnings per share for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.